GLOBAL TECH INDUSTRIES GROUP, INC. SIGNS LETTER OF INTENT WITH ALT 5 SIGMA, INC. TO EXPLORE BUSINESS COMBINATION

Written by Customer Service on April 10, 2021. Posted in Public Companies.

New York, NY, April 10, 2021 (GLOBE NEWSWIRE) — (GTII:OTCQB) Global Tech Industries Group, Inc. (OTCQB: GTII) (“GTII” or the “Company”), www.gtii-us.com, a Nevada corporation announced on April 9, 2021, that the Company had engaged Alt5 Sigma, Inc. to provide the platform for creating NFTs for its upcoming art assets, as well as future assets requiring tokenization. During their discussions, both companies recognized that a unique synergy may exist between the two companies that warranted further exploration. Both sides believe that a corporate structure combining GTII and Alt5 Sigma could be extremely and mutually beneficial to both companies’ shareholders. As such, the parties have entered into a non-binding Letter of Intent to explore the options for such a business combination, and attempt to arrive at an agreement that is beneficial...

Cameco remettra en service sa mine de Cigar Lake en avril

Written by Customer Service on April 10, 2021. Posted in Public Companies.

SASKATOON, Saskatchewan, 10 avr. 2021 (GLOBE NEWSWIRE) — Cameco (TSX: CCO; NYSE: CCJ) a annoncé aujourd’hui son intention de relancer la production en avril dans sa mine d’uranium de Cigar Lake, située dans le nord de la Saskatchewan. La production à Cigar Lake a été interrompue temporairement en décembre 2020 en raison de risques croissants posés par la pandémie de coronavirus (COVID-19). À cette période, le nombre de travailleurs disponibles dans les zones critiques diminuait en raison de la pandémie, du fait du nombre plus grand de personnes écartées ou résidant dans des communautés soumises à des restrictions de voyage liées à la pandémie. « Notre priorité absolue est la sécurité de nos travailleurs, de leurs familles et des communautés, a déclaré le président et chef de la direction de Cameco, Tim Gitzel. Au cours...

C4 Therapeutics Presents Preclinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the AACR Annual Meeting 2021

Written by Customer Service on April 10, 2021. Posted in Public Companies.

– CFT7455 Demonstrated High Cereblon Binding Affinity and Rapid, Deep IKZF1/3 Degradation Enabling Activity across a Panel of Multiple Myeloma Cell Lines Including IMiD-Resistant Models – – CFT7455 Promotes Sustained Degradation of IKZF1/3 and Durable Anti-tumor Response, Including Regressions in an IMiD-Insensitive Myeloma Tumor Xenograft Model – – CFT7455 Phase 1/2 Trial in Multiple Myeloma and Non-Hodgkin Lymphomas On Track for 1H 2021 Initiation – WATERTOWN, Mass., April 10, 2021 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today presented preclinical data for CFT7455, the Company’s lead program, a MonoDACTM degrader targeting IKZF1/3 for the treatment of hematologic...

iRhythm® Technologies Announces Conference Call to Discuss Medicare Administrative Contractor (MAC) Novitas’s Updated Rate Publication

Written by Customer Service on April 10, 2021. Posted in Public Companies.

SAN FRANCISCO, April 10, 2021 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced that it will host a conference call to discuss the recent publication by Novitas Solutions (“Novitas”) of rates applicable to the Current Procedural Terminology (CPT) codes 93243 and 93247. On April 10, 2021, Novitas published updated reimbursement rates for codes 93243 and 93247 at $103 and $115, respectively. The updated rates are retroactive to January 1, 2021 and replace rates initially published on January 29, 2021. iRhythm is assessing the impact of the updated Novitas rates on its business and will provide comments on a conference call on April 12, 2021. Webcast and Conference Call InformationiRhythm will host a conference call...

Zentalis Pharmaceuticals Announces Promising Initial Data Presented in a Late-Breaking Session at AACR on ZN-c3, its WEE1 Inhibitor, in Patients with Advanced Solid Tumors

Written by Customer Service on April 10, 2021. Posted in Public Companies.

ZN-c3 demonstrated single agent activity, generating Exceptional Responses in a range of heavily pre-treated solid tumors ZN-c3 was safe and well-tolerated Identified recommended Phase 2 dose for ZN-c3 to be 300 mg QD with continuous dosing Announces plan to start Phase 1/2 osteosarcoma trial in Q3 2021 Company to host webcast event with key opinion leaders on Monday, April 12 at 4:00 p.m. EDT NEW YORK and SAN DIEGO, April 10, 2021 (GLOBE NEWSWIRE) — Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced initial efficacy and safety data from the Phase 1 dose-escalation portion of its ongoing Phase 1/2 clinical trial of ZN-c3 in patients with advanced solid tumors...

PMV Pharma Presents Late-Breaking Preclinical Data on Lead Product Candidate PC14586 at the American Association for Cancer Research Annual Meeting 2021

Written by Customer Service on April 10, 2021. Posted in Public Companies.

PC14586 selectively stabilizes the p53 Y220C mutant and restores p53 activity Robust in vivo tumor regression observed with once daily oral dosing Pharmacodynamic biomarkers of p53 activation developed for clinical trials PC14586 is being tested in a Phase 1/2 clinical trial in patients with advanced solid tumors that have a p53 Y220C mutation CRANBURY, N.J., April 10, 2021 (GLOBE NEWSWIRE) — PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today presented preclinical data on PC14586, the Company’s first-in-class, tumor-agnostic, small molecule p53 reactivator at the American Association for Cancer Research Annual Meeting 2021. “The preclinical data provide compelling evidence that PC14586 selectively...

Oncocyte Presents New Data at 2021 American Association for Cancer Research Annual Meeting Demonstrating Potential for Pan-Cancer Utility of DetermaIO™

Written by Customer Service on April 10, 2021. Posted in Public Companies.

Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer DetermaIO identified additional immunotherapy responsive patients missed by commonly used biomarkers Data supports potential utility of DetermaIO test across multiple solid tumors as predictor of response to Immune Checkpoint Inhibitor therapy in estimated $3 billion market in the United States KOL Webinar discussing results to be held on April 19 at 11:30 AM EDT/8:30 AM PDT IRVINE, Calif., April 10, 2021 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, presented new data at the American Association for Cancer Research (AACR) Annual...

Theratechnologies Presents New In Vivo Pre-Clinical Data at AACR Demonstrating Significant Anti-Tumor Activity of TH1902 in All Studied Cancer Types

Written by Customer Service on April 10, 2021. Posted in Public Companies.

MONTREAL, April 10, 2021 (GLOBE NEWSWIRE) — Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that new in vivo preclinical data were presented at the 2021 Annual Meeting of the American Association for Cancer Research (AACR). These data demonstrated sustained tumor regression, better anti-tumor activity and tolerability with TH1902 compared to docetaxel alone in all cancer types studied, namely melanoma, pancreatic, ovarian, endometrial, colorectal and triple-negative breast cancers. The anti-tumor effect of TH1902 persisted longer post-treatment than with docetaxel alone. TH1902 is the Company’s lead investigational peptide-drug conjugate (PDC) derived from its SORT1+ Technology™. “The FDA fast-track...

Theratechnologies présente de nouvelles données précliniques in vivo démontrant une importante activité antitumorale du TH1902 dans tous les types de cancers étudiés

Written by Customer Service on April 10, 2021. Posted in Public Companies.

MONTRÉAL, 10 avr. 2021 (GLOBE NEWSWIRE) — Theratechnologies (Theratechnologies) (TSX : TH) (NASDAQ : THTX), une société biopharmaceutique axée sur le développement et la commercialisation de traitements innovateurs, a annoncé aujourd’hui que de nouvelles données précliniques in vivo ont été présentées au 2021 Annual Meeting of the American Association for Cancer Research (AACR). Ces données ont démontré une régression tumorale durable, une meilleure activité antitumorale et une meilleure tolérance avec le TH1902 comparativement au docétaxel seul dans tous les types de cancers étudiés, notamment les cancers de la peau, du pancréas, de l’ovaire, de l’endomètre, du côlon et du sein triple négatif. L’effet antitumoral du TH1902 persiste plus longtemps après le traitement qu’avec le docétaxel seul. Le TH1902 est le principal conjugué...

F-star Therapeutics Shows Differentiation of FS222 in 2021 AACR Poster

Written by Customer Service on April 10, 2021. Posted in Public Companies.

CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) — F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announces that preclinical data from FS222, a potentially best-in-class tetravalent bispecific antibody targeting both CD137 and PD-L1 will be presented in a poster at the 2021 American Academy of Cancer Research (AACR) Annual Meeting, taking place virtually from April 10-15 and May 17-21. Poster #1864, entitled ‘FS222, a Tetravalent Bispecific Antibody Targeting CD137 and PD-L1, is Designed for Optimal CD137 Interactions Resulting in Potent T cell Activation Without Toxicity’ will be available via on-demand viewing starting today, April 10, at 8:30...

Day: April 10, 2021

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice